title: Down-regulation of survivin suppresses uro-plasminogen activator through transcription factor JunB.
abstract: Survivin, a member of the inhibitors of apoptosis protein family, is expressed during development and in various human cancers. However, the clinical relevance of survivin in cancer is still a matter of debate. Genes induced by hepatocyte growth factor (HGF) were screened using cDNA microarray technology in the stomach cancer cell lines, NUGC3 and MKN28. The levels of JunB, survivin, and uro-plasminogen activator (uPA) were up-regulated in cells treated with HGF in a dose-dependent manner. HGF-induced up regulation of JunB, survivin, and uPA was inhibited by pre-treatment with a MEK inhibitor (PD 98059). HGF-induced up-regulation of uPA was repressed by survivin knockdown. HGF enhanced the binding activity of JunB to the survivin promoter in control cells, but not in the JunB-shRNA cells. Transfection with survivin- shRNA resulted in a decrement of cell proliferation, as determined with MTT assays. In an in vitro invasion assay, significantly fewer cells transfected with survivin shRNA than control cells were able to invade across a Matrigel membrane barrier. In conclusion, survivin appeared to play an important role in the up-regulation of uPA induced by HGF via JunB and might contribute to HGF-mediated tumor invasion and metastasis, which may serve as a promising target for gastric cancer therapy.
authors: Department of Hematology-Oncology, College of Medicine, Yeungnam University, Daegu 705-717, Korea.
authors: Kyung Hee
authors: KH
authors: Lee
authors: Eun Young
authors: EY
authors: Choi
authors: Sung Ae
authors: SA
authors: Koh
authors: Min Kyoung
authors: MK
authors: Kim
authors: Kyeong Ok
authors: KO
authors: Kim
authors: Si Hyung
authors: SH
authors: Lee
authors: Byung Ik
authors: BI
authors: Jang
authors: Se Won
authors: SW
authors: Kim
authors: Sang Woon
authors: SW
authors: Kim
authors: Sun Kyo
authors: SK
authors: Song
authors: Joon Hyuk
authors: JH
authors: Choi
authors: Jae-Ryong
authors: JR
authors: Kim
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005419:Flavonoids / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D017228:Hepatocyte Growth Factor / Q000494:pharmacology*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D009361:Neoplasm Invasiveness; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D016755:Proto-Oncogene Proteins c-jun / Q000235:genetics / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000077022:Survivin; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics*
chemical_list: C107489:BIRC5 protein, human; D005419:Flavonoids; D051034:Inhibitor of Apoptosis Proteins; D016755:Proto-Oncogene Proteins c-jun; D000077022:Survivin; D017228:Hepatocyte Growth Factor; D020930:MAP Kinase Kinase Kinases; D014568:Urokinase-Type Plasminogen Activator; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one